Sivik Global Healthcare LLC Makes New Investment in Bio-Rad Laboratories, Inc. $BIO

Key Points

• Sivik Global Healthcare LLC acquired 18,000 shares of Bio-Rad Laboratories, valued at approximately $4.34 million, making it the 25th largest position in their investment portfolio.
• Bio-Rad reported earnings of $2.61 EPS for the latest quarter, exceeding analysts' expectations and showing a 2.1% increase in revenue compared to the same quarter last year.
• Approximately 65.24% of Bio-Rad's stock is held by institutional investors and hedge funds, reflecting significant interest from major financial entities.

Sivik Global Healthcare LLC bought a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 18,000 shares of the medical research company's stock, valued at approximately $4,344,000. Bio-Rad Laboratories accounts for approximately 1.2% of Sivik Global Healthcare LLC's investment portfolio, making the stock its 25th largest position. Sivik Global Healthcare LLC owned about 0.07% of Bio-Rad Laboratories as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Quarry LP acquired a new position in Bio-Rad Laboratories in the 1st quarter valued at approximately $29,000. Allworth Financial LP grew its holdings in shares of Bio-Rad Laboratories by 260.0% during the 1st quarter. Allworth Financial LP now owns 144 shares of the medical research company's stock valued at $36,000 after acquiring an additional 104 shares in the last quarter. UMB Bank n.a. increased its stake in shares of Bio-Rad Laboratories by 89.8% in the second quarter. UMB Bank n.a. now owns 167 shares of the medical research company's stock worth $40,000 after acquiring an additional 79 shares during the last quarter. Headlands Technologies LLC raised its holdings in shares of Bio-Rad Laboratories by 64.1% during the first quarter. Headlands Technologies LLC now owns 356 shares of the medical research company's stock worth $87,000 after acquiring an additional 139 shares in the last quarter. Finally, Twin Tree Management LP acquired a new stake in Bio-Rad Laboratories during the first quarter valued at $87,000. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Bio-Rad Laboratories Price Performance

Shares of Bio-Rad Laboratories stock opened at $298.30 on Friday. The company has a current ratio of 5.12, a quick ratio of 3.67 and a debt-to-equity ratio of 0.17. The firm has a fifty day simple moving average of $286.07 and a 200-day simple moving average of $256.44. The stock has a market capitalization of $8.07 billion, a price-to-earnings ratio of 25.43 and a beta of 0.97. Bio-Rad Laboratories, Inc. has a 1-year low of $211.43 and a 1-year high of $387.99.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its earnings results on Thursday, July 31st. The medical research company reported $2.61 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.93 by $0.68. The business had revenue of $651.60 million for the quarter, compared to analyst estimates of $614.82 million. Bio-Rad Laboratories had a net margin of 12.50% and a return on equity of 4.01%. Bio-Rad Laboratories's revenue was up 2.1% compared to the same quarter last year. During the same period last year, the business posted $3.11 EPS. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Zacks Research raised Bio-Rad Laboratories from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 26th. Wells Fargo & Company raised their price objective on shares of Bio-Rad Laboratories from $245.00 to $265.00 and gave the company an "equal weight" rating in a research report on Friday, August 1st. Weiss Ratings reissued a "sell (d)" rating on shares of Bio-Rad Laboratories in a research report on Saturday, September 27th. Wall Street Zen lowered shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Friday, August 22nd. Finally, Royal Bank Of Canada lifted their price objective on shares of Bio-Rad Laboratories from $387.00 to $409.00 and gave the company an "outperform" rating in a research note on Friday, August 1st. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Bio-Rad Laboratories has an average rating of "Hold" and a consensus target price of $333.50.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.